Αρχειοθήκη ιστολογίου

Τρίτη 19 Φεβρουαρίου 2019

Asthma with multiple allergic comorbidities is associated with complete response to omalizumab

Abstract

Patients with severe asthma constitute a heterogeneous population, and different phenotypes have been identified both in adults and children. Severe asthma affects 4.5% of children with current asthma. Several studies have shown that omalizumab, a humanized anti‐IgE monoclonal antibody, is effective in exacerbations and asthma control, and well tolerated in children with severe allergic asthma. However, as biotherapy response varies among patients, it is important to clearly define which children will benefit the most from treatment.

This article is protected by copyright. All rights reserved.



http://bit.ly/2trpgo1

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου